National HIV Vaccine Awareness Day

HIV mutates rapidly, exists as many different subtypes around the world, and integrates its genetic material into human cells, which makes it very difficult for the immune system to recognize and clear.

The virus also targets key immune cells (CD4 T cells) that normally help coordinate responses to infection.

Unlike diseases such as measles, the human immune system has never been known to completely clear HIV on its own, so researchers do not have a natural “template” for protective immunity to copy in a vaccine.  

HIV treatment, known as antiretroviral therapy, is used by people who already have HIV to control the virus, protect their immune system, and greatly reduce the risk of transmission.

Pre-exposure prophylaxis (PrEP) is medicine taken by HIV-negative people to lower their risk of getting HIV from sex or injection drug use.

A preventive HIV vaccine would be given to HIV-negative people to “train” the immune system in advance so it can block infection if the virus is encountered, in the same way that vaccines work for many other diseases.

These tools would complement each other rather than replace one another.  

The basic safety principles are the same as for other vaccines, with early-phase clinical trials focused on careful safety monitoring before larger studies are allowed.

However, HIV vaccine trials receive particular ethical and safety scrutiny because participants often live in communities with ongoing HIV transmission and stigma.

Trials must ensure that volunteers receive comprehensive HIV prevention services, frequent testing, and counseling and that any person who becomes infected during a trial is quickly linked to high-quality treatment.

Independent ethics committees and data safety monitoring boards oversee these studies throughout their duration.  

HIV vaccine candidates used in human trials are designed so they cannot cause HIV infection.

They typically use pieces of HIV, genetic instructions for making HIV proteins, or harmless viral “vectors” that carry HIV genes but cannot reproduce like HIV.

None of these approaches contain whole, replication-competent HIV. Participants are still regularly tested because they may be exposed to HIV in their everyday lives, not from the vaccine itself.  

Mathematical models suggest that even a partially effective HIV vaccine, if widely used, could prevent millions of new infections over time, especially in regions with high HIV incidence.

Vaccination could reduce the number of people who acquire HIV, which in turn would lower the number of people who might transmit it, creating a cumulative effect across communities.

Combined with testing, treatment, PrEP, and harm reduction services, a vaccine is expected to significantly accelerate progress toward long-term control of the epidemic.  

Public health agencies do not expect a single intervention to eliminate the need for others.

Early HIV vaccines are likely to offer partial protection that may vary by person and over time. For that reason, experts anticipate that an HIV vaccine will be used alongside existing tools such as condoms, PrEP, treatment-as-prevention (undetectable equals untransmittable, or U=U), and harm reduction programs.

Using several prevention strategies together is still considered the most reliable way to lower HIV risk at both individual and population levels.  

Common misconceptions include the ideas that an HIV vaccine would infect people with HIV, that vaccine trials use people as “guinea pigs” without protections, or that a vaccine would immediately end the need for other prevention methods.

In reality, HIV vaccines in trials cannot cause HIV infection, clinical studies follow strict ethical and safety rules, and researchers are clear that any future vaccine will work best as part of a broader prevention strategy.

Ongoing community education, transparency about trial results, and involvement of affected communities in research planning are key ways scientists and advocates address these myths.